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Light chain amyloidosis (AL), the most common systemic amyloidosis, is caused by the overproduction 
and the aggregation of monoclonal immunoglobulin light chains (LC) in target organs. Due to 
genetic rearrangement and somatic hypermutation, virtually, each AL patient presents a different 
amyloidogenic LC. Because of such complexity, the fine molecular determinants of LC aggregation 
propensity and proteotoxicity are, to date, unclear; significantly, their decoding requires investigating 
large sets of cases. Aiming to achieve generalizable observations, we systematically characterised a 
pool of thirteen sequence-diverse full length LCs. Eight amyloidogenic LCs were selected as responsible 
for severe cardiac symptoms in patients; five non-amyloidogenic LCs were isolated from patients 
affected by multiple myeloma. Our comprehensive approach (consisting of spectroscopic techniques, 
limited proteolysis, and X-ray crystallography) shows that low fold stability and high protein dynamics 
correlate with amyloidogenic LCs, while hydrophobicity, structural rearrangements and nature of 
the LC dimeric association interface (as observed in seven crystal structures here presented) do not 
appear to play a significant role in defining amyloid propensity. Based on the structural and biophysical 
data, our results highlight shared properties driving LC amyloid propensity, and these data will be 
instrumental for the design of synthetic inhibitors of LC aggregation.
Systemic amyloidoses are protein misfolding diseases caused by deposition of proteins as fibrillar aggregates in 
target organs1. In these disorders, the amyloidogenic protein precursor is produced at sites distant from those 
of deposition, being then transported to the tissues through blood2. Light chain amyloidosis (AL) is the most 
frequent systemic form, with an incidence of approximately 10 cases per million-persons/year; it is caused by dep-
osition of excess monoclonal immunoglobulin light chains (LCs) produced by a bone marrow plasma cell clone3. 
Since the incidence of AL increases with age, the socio-economic impact of this devastating disease is expected to 
grow within the ageing population of industrialized countries.
AL is a heterogeneous disease, both in terms of causative proteins and of the pattern of organ involvement. 
The extreme variability among LCs, caused by genetic rearrangement and somatic hypermutation4, translates into 
the fact that virtually every monoclonal LC is unique in its amino acid sequence. The clinical phenotype of AL is 
also polymorphic, most patients showing multi-organ involvement at presentation2: involvement of the heart, in 
particular, is frequent (~75% of cases) and dictates the prognosis2,3,5. A growing body of experimental and clinical 
evidences from patients with cardiac involvement indicate that damage is not only caused by fibril deposits, but 
also by pre-fibrillar amyloidogenic LCs, which are themselves directly toxic for target cells6–9.
Understanding the specific properties of different LCs in their soluble native state, therefore, appears as a 
rational approach to explore the determinants of amyloid formation, organ tropism and dysfunction in vivo. 
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Because of insufficient insight, no treatments exist yet to block fibril formation and prevent tissues damage. In 
fact, the current therapeutic strategies are based essentially on halting the production of amyloidogenic LCs from 
the plasma cell clone by means of chemotherapy5.
Structural characterization has shown that LCs assemble into homodimers, each monomer consisting of two 
immunoglobulin domains10, where the N-terminal variable domain (VL) displays high sequence variability. In 
particular, the three hypervariable complementarity determining regions (CDR) that target specific antigens are 
located in the VL domain. The C-terminal constant domain (CL), on the contrary, displays highly conserved 
sequence within the λ and the κ isotypes. To date, most studies dealing with the biophysical and structural 
properties of amyloidogenic LCs have focused specifically on VL domains, as they are abundant in fibrils: typ-
ically, VL domains belonging to amyloidogenic LCs are thermodynamically and kinetically unstable, while the 
three-dimensional structures of amyloidogenic and non-amyloidogenic VL studied match closely11–15. However, 
many observations stress the relevance of studying full length LCs: (i) although VL are abundant in fibrils, the full 
length LCs and CL domains have also been found in deposits12,16–18; (ii) so far, FL LCs and not truncated forms, 
have been found soluble in blood and serum19; iii) recent reports underline the relevance of the CL domain in 
determining both the biophysical properties and the aggregation propensity of LCs20–23.
The biophysical characterizations hitherto reported have mostly focused on the pairwise comparisons of one 
amyloidogenic with one non-amyloidogenic LC11,16,20,21,24. At the light of the mentioned sequence variability4, 
the results of such studies may prove difficult to generalize. In an effort to extend our views, here we present 
a comprehensive biophysical and structural characterization of a pool of eight amyloidogenic LCs originating 
from different patients (thus endowed with different amino acid sequences). Among all patients who overexpress 
one LC variant, only a subset develops AL (specific germline genes typically of the λ isotype are overrepresented 
among amyloidogenic LCs25–27), therefore five LCs not displaying amyloid propensity in patients were included 
as controls in our test pool. We explored the correlation between the aggregation propensity observed in patients 
and the LC molecular properties that may elicit misfolding, and are held to be associated with proteotoxicity. Our 
results provide insight on the fundamental molecular properties of pathogenic LCs, and in parallel suggest con-
cepts for the design of therapeutic approaches to AL directly targeting circulating LC molecules.
Results
Set-up of the LC test pool. In order to explore a most general context, while coping with the issue of high 
LC sequence variability, we devised an experimental approach based on three criteria. (i) Our biophysical and 
structural characterization covered thirteen LCs from distinct patients. LCs were distributed in two groups: a 
set of eight amyloidogenic LCs responsible for severe cardiac involvement and symptoms in patients (hereafter, 
H LC), and a set of five non amyloidogenic LCs isolated from patients affected by multiple myeloma for which 
no amyloid aggregation or proteotoxicity was observed in patients (hereafter, M LC) (Table 1 and Table S1). 
(ii) All the selected LCs were of the λ isotype, which is overrepresented among amyloidogenic LCs (approxi-
mately 75%)2,28, all the H LCs (except H10 from germline 1–36) belong to germlines commonly found among AL 
patients29. However, the LCs were distributed across different families and germlines to avoid focusing on family/
germline-specific properties (Table 1 and Fig. 1). (iii) All proteins used in the experiments were full length LCs, 
since the blood concentration of these species in each patient directly correlates with the severity of organ dys-
function, particularly regarding the heart (Table S1)5,8. Our experiments focused on the properties of native LCs, 
since ultimately these represent the circulating reservoir of aggregation prone material; LCs were either expressed 
recombinantly30 or purified from patients’ urines (Table 2).
LC fold stability. Protein stability within the two LC groups was assessed using three different and comple-
mentary approaches. Unfolding temperatures for each LC were monitored by Far-UV circular dichroism (CD), 
LC code Germline Gender, age Diagnosis Organs involved Serum λ FLC (mg/l)
H3 1c (IGLV1-44) M, 65 AL H 252
H6 1b (IGLV1-51) F, 72 AL H, K, PNS 248
H7 1b (IGLV1-51) M, 45 AL H 477
H9 2c GLV2-8) M, 59 AL H, ST 699
H10 1a (IGLV1-36) M, 73 AL H, L 475
H15 6a (IGLV6-57) M, 53 AL H, PNS, ST 839
H16 2a2 (IGLV2-14) M, 72 AL H, K 383
H18 3 l (IGLV3-19) M, 69 AL H, ST, PNS 509
M2 2b2 (IGLV2-23) M, 65 MM — 1140
M7 3 l (IGLV3-19) F, 71 MM — 6130
M8 2b2 (IGLV2-23) M, 48 MM — 573
M9 2b2 (IGLV2-23) M, 61 MM — 8510
M10 2a2 (IGLV2-14) M, 55 MM — 12200
Table 1. Biochemical and clinical features of H and M LCs (for more extended information, with a complete set 
of clinical data, see Table S1). Abbreviations: M, male; F, female; MM, multiple myeloma; H, Heart; K, Kidney; 
ST, Soft Tissues; PNS, Peripheral Nervous System; BJ, Bence Jones protein (monoclonal urinary free light 
chains); FLC, Free Light Chains.
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by Near-UV CD, and by 8-anilino-1-naphthalenesulfonic acid (ANS) binding and fluorescence signal (Fig. 2). 
LC unfolding monitored through these spectroscopic methods provides information on the loss of secondary 
structure, of tertiary structure, and on the exposure of buried hydrophobic residues to the solvent, respectively. 
As previously reported the unfolding of full length LCs is not reversible (data not shown)22, thus all temperatures 
corresponding to the unfolding inflection points should be considered apparent melting temperatures (Tmapp). 
The Far and Near-UV spectra of all LCs under native conditions are shown in Fig. S1.
In general, H LCs (warm colours in Fig. 2) displayed lower Tmapp compared to M LC (cool colours in Fig. 2), 
as determined from the Far-UV and Near-UV CD temperature ramps shown in Fig. 2A and B, respectively. 
However, low Tmapp values do not correlate perfectly with LCs amyloidogenicity, since M7 and M10 LCs unfold at 
temperatures close to those of the most stable H LCs (Table 2). Interestingly, most LCs show a one-step unfolding 
process, but three H LCs (H3, H6, H7) and one M LC (M9) display a two-step process, observed both in Far- 
and Near-UV temperature ramps (Fig. 2A,B). At the protein concentration required for Near-UV experiments 
four LCs (H10, M2, M8, M10) precipitated before the unfolding process was complete, thus Tmapp could not be 
determined. Nevertheless, the Tmapp values obtained by monitoring the unfolding both by Near-UV and Far-UV 
CD, show a good agreement (Table 2), indicating that for these LCs the loss of secondary and tertiary structures 
are simultaneous processes. Student’s test calculated using Tmapp values determined by Far-UV indicate that the 
differences between H and M-LCs are significantly different (P < 0.005).
While the Near-UV CD signal is strongly dependent on Trp residues, and may therefore provide rather local 
information about the unfolding process, an increase in ANS fluorescence indicates the exposure of hydrophobic 
residues from the protein core. Inspection of Fig. 2C shows that unfolding monitored by ANS fluorescence is com-
patible with exposure of the hydrophobic core residues in a one-step process in all the analysed LCs. This observation 
rules out that stepwise unfolding of the two distinct domains occur in the LCs (H3, H6, H7, M9), which display 
Figure 1. Multialignment of all thirteen LCs used in this work: the residues conserved in all sequences are 
highlighted in yellow, residues involved in the VL – VL interface in all the crystal structures are highlighted in 
cyan, while the residues belonging to the three CDRs are shown in red.
LC Source Tmapp Far UV (°C) Tmapp Near UV (°C)1 ONSET ANS SIGNAL (°C) Hydrophobicity (%) Proteolysis2 Trypsin sites
H3 Rec (40.2) – 54.4 ± 0.8 (44.5)—53.1 54.8 23.1 +++ 14
H6 Rec (43.9) – 54.5 ± 0.8 (45.3)— 55.3 23.1 +++ 18
H7 Rec (42.8) – 54.7 ± 0.5 (48.7) – 56.2 54.8 23.6 ++ 16
H9 BJP 52.0 ± 0.8 54.0 55.8 21.3 +++ 14
H10 BJP 54.9 ± 0.5 54.3 58.3 23.7 ++ 14
H15 BJP 55.6 ± 0.6 — 54.7 21.8  + + 14
H16 BJP 51.3 ± 0.7 51.9 54.5 22.3 +++ 13
H18 BJP 52.4 ± 0.5 51.1 51.5 22.9 ++ 13
M2 BJP 61.5 ± 0.8 — 63.9 23.0 + 15
M7 BJP 54.7 ± 0.5 55.3 58.8 22.4 + 15
M8 BJP 72.6 — 73.5 22.7 + 15
M9 Rec/BJP (63.2) – 68.2 ± 1.4 (58.8) – 67.7 62.8 24.2 + 15
M10 BJP 58.0 ± 0.6 — 56.1 21.5 + 15
Table 2. Biophysical properties assessed for H and M LCs. Rec, recombinantly expressed LC; BJP, Bence Jones 
proteins purified from urines. (1): some Tmapp values could not be measured due to protein aggregation during 
the temperature ramp. (2): +++:  < 20%, ++: 20–60%, +:  > 60% fraction of uncleaved protein after 180 min.
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two-step unfolding when monitored by CD signal; thus the temperatures corresponding to the first inflection points 
are written in parenthesis in Table 2. The onset of the ANS signal, but not the inflection point of the curves, correlates 
well with the Tmapp values calculated from the CD signals; such apparent discrepancy suggests that the hydrophobic 
core is exposed only at an advanced state of unfolding, which leads to an (apparent) systematic Tmapp overestimation 
in ANS temperature unfolding. Taken together these data suggest that the loss of tertiary and of secondary structures 
are simultaneous processes, indicating that LC dimers unfold through a cooperative process. Importantly, the ANS 
spectra recorded under native conditions yield undistinguishable low signals (data not shown), suggesting that under 
such conditions none of the LCs studied in this work expose relevant hydrophobic patches to the surface.
LC dynamics. In order to obtain an indirect assessment of protein dynamics, limited proteolysis of the differ-
ent LCs using trypsin was performed. Typically, fast proteolysis kinetics correlate with marked protein dynamics; 
conversely, protein rigidity correlates with slow proteolysis kinetics. In our hands, many but not all of the LCs 
belonging to the explored set displayed an unexpected resistance to proteolysis by trypsin and chymotrypsin 
(data not shown); controlled shaking (i.e. simulating shear forces) was tested to increase the kinetics of prote-
olysis without any effect (data not shown). Thus, in order to perform proteolysis in an adequate time frame, a 
sub-denaturant concentration of urea (1 M) was added to the protein solutions: under such conditions all LCs 
displayed CD spectra indistinguishable from those recorded in the absence of 1 M urea (data not shown).
Figure 3 shows the SDS-PAGE monitoring the controlled proteolysis experiments and the plotted fraction 
of uncleaved protein at different time points. Analysis of the data shows that the kinetics of proteolysis correlate 
well with amyloid propensity (Fig. 3B): H3, H6, H7, H9, and H16 are almost or totally proteolysed after 60 min-
utes, and more than 50% of H10, H15 and H18 LCs is cleaved after three hours. This is in stark contrast with the 
behaviour observed for the five M LCs, which are consistently more resistant to trypsin, in all cases more than 
60% of the M LCs remaining uncleaved at the end of the experiment (total of 3 hours). The number of potential 
trypsin cleavage sites for each LC is reported in Table 2; such numbers vary and do not correlate with the kinetics 
of proteolysis, suggesting that the observed kinetics underlie genuine differences in protein dynamics or confor-
mational flexibility. Student’s test calculated using the percentage of uncleaved LC at the end of the experiment 
indicates that the kinetics of proteolysis between H and M-LCs are significantly different (P < 0.0005).
The pattern of proteolysis varied among different LCs. SDS-PAGE gel analysis showed that for most LCs no 
bands corresponding to specific LC fragments were present, indicating that the LCs had been directly proteolysed 
to small peptides; although in a few cases discrete bands were detected, they proved unstable over the entire pro-
teolysis experiment (Fig. 3A). Overall, these observations suggest that the proteolytic path is distinct in different 
LCs, and that no stable LC domains (e.g. VL, CL domains or other fragments) can be isolated during proteolysis 
under the conditions tested.
Figure 2. Thermal stability of H and M LCs. Far-UV (A) and Near-UV (B) CD temperature ramps of the two 
sets of LCs used in this study. (C) Temperature ramps followed using ANS fluorescence. The H and M LCs are 
shown with warm and cool colours, respectively.
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Structural analyses of H and M LCs. In order to gain high-resolution structural insight, all the thirteen 
LCs were screened for crystal growth. Five H LCs (H3, H6, H7, H9 and H10) and two M LCs (M7 and M8) were 
successfully crystallized and their 3D-structures solved. Each of the seven LCs crystallized in a different space 
group, with distinct crystal packing; the crystallographic resolutions achieved ranged from 2.70 Å (H7) to 1.65 Å 
Figure 3. (A) SDS-PAGE monitoring the limited proteolysis of H and M LCs by trypsin. The first sample was 
taken one minute after trypsin addition (1) and then at 10, 20, 30, 60, 90, 120, 150 and 180 min of reaction 
time. In LC a standard amount of the corresponding LC loaded onto the gel without adding trypsin (Tr). 
MM indicates molecular markers their mass is expressed in kDa. All SDS-PAGE were run under reducing 
conditions. Raw images of the all SDS-PAGE are shown in Figure S4 (B) Kinetics of LC proteolysis. The intensity 
of the band corresponding to the uncleaved LC has been quantified at different time points and plotted. As 
starting point the amount of protein present in the LC sample was chosen. Each curve results from three 
independent proteolysis experiments. The curves are colour coded as in Figs 2 and 3.
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(H9) (Table S2). The crystal structures were all refined to satisfactory refinement parameters (Table S2); in all 
cases the LCs were dimeric (Fig. 4A), with an overall quaternary arrangement closely matching that of the pre-
viously reported LC dimers10. Mass spectrometry and non-reducing SDS-PAGE indicated that 100% of the LC 
dimers were covalently linked by a disulphide bond located at the chain C-terminus (data not shown). However, 
due to underlying local flexibility, only for H9 a well-defined electron density for such C-terminal intermolecular 
disulphide bond is visible (Fig. S2).
VL and CL domains display very different structural properties in the seven crystal structures. CL domains 
(res 115–214) are typically characterized by high quality electron density, are all very well superposable, and 
the dimeric CL–CL arrangement is clearly conserved in all the analysed structures (root mean square deviations 
-r.m.s.d.- generally fall below 1.0 Å over the entire CL–CL dimer - Table S3A and Fig. 4B-bottom). The linker 
regions connecting VL and CL domains (residues 110–115) allow evident variability in the mutual orientation 
of VL and CL domains, which is described by the elbow angles (Table S2) spanning from 107.99° (H7) to 157.36° 
(M8). (Interestingly, the greatest elbow angles were found in the M LCs structures, as for previously reported 
works10. For this reason, the r.m.s.d. values calculated for the full length LCs are not meaningful and are not 
reported.
Contrary to what has been observed for the CL domains, the electron density quality for the VL domains 
(residues 1–109) greatly differs among the seven crystal structures. With the only exception of one of the two VL 
domains of the M7 LC dimer, the two β-sheets building the VL domains are in general easily traceable; however 
the quality of the electron density for the CDR loops is markedly dependent on the LC crystal structure consid-
ered. In H6 and M8 dimers all six CDRs (three for each LC monomer) are traceable in the electron density; in H9 
and H10 five out of six are traceable, in H7 three, and in H3 and M7 only two CRDs are traceable. Such different 
behaviours, which are related to the intrinsic CDR conformational adaptability, do not correlate with LC aggrega-
tion propensity or with the flexibility assessed by limited proteolysis. Thus, the observed variety of CDR confor-
mations are likely due to different CDR amino acid sequences, but may also reflect different chemical conditions 
for crystal growth and different crystal packing.
The above concept is further stressed by the fact the VL domain tertiary structures match closely (Table S3B 
and Fig. 4C), while conformations of their CDRs are rarely superposable. The inspection of the VL dimer provides 
a relevant example: the fine details of the VL–VL association interface are LC-specific, depending on: (i) sequence 
variability, which likely causes the mutual reorientation of VL domains by some degrees, as observed in the differ-
ent structures (Fig. 4B-top); and, (ii) CDR conformational variability (and traceability in the electron density). In 
some cases (H6, H9, H10) CDR3 (residues 89–97) participates in the interface; both CDR3s in the H7 dimer lack 
electron density, while in M7 and M8 CDR3 residues are located far from the VL–VL interface.
Despite these fine differences, all the structures here presented, except for M8, display an overall conserved 
VL–VL quaternary assembly and association interface (Table S3C and Fig. 4B and E). In the structures of all H LCs 
and in M7, the association interface is roughly symmetric, and is located on the five-stranded beta sheet (strands 
1, 3, 4, 7, 8), where the 3, 4, 7, 8 strands establish the intermolecular contacts. Figure 4D shows the region involved 
in the VL–VL interface together with the most relevant and conserved residues. Only the VL–VL interface in M8 is 
markedly different, one VL domain being rotated and resulting in an asymmetric VL–VL interface (Fig. 4E). As for 
the other structures, in one VL domain of M8 strands 3, 4, 7 and 8 participate to the dimeric interface, while only 
strands 1 and 8 of the facing/rotated VL domain provide association contacts.
The calculated free energy gain associated with dimer formation, and the resulting dimer interface areas 
(Table S4), do not correlate with amyloidogenicity. In particular, M8 LC, which is the most stable LC against 
temperature (Table 2), displays the smallest dimer interface area with the lowest calculated free energy change for 
quaternary assembly, compared to all other considered LCs (Table S4).
Discussion
The five M LCs presented in this study are found in patients at extremely high concentrations, much higher than 
the average concentration of the H LCs (Table 1 and S1), and yet, through the years, the M proteins remain soluble 
and do not aggregate. Our study aimed to explore the biophysical and structural properties that correlate with 
LC amyloid aggregation; to reach most general conclusions, we analysed a set of thirteen patient-derived LCs, 
focusing on some of the commonly proposed structural and biophysical determinants of protein aggregation and 
toxicity31, such as fold stability, protein overall hydrophobicity, protein dynamics and flexibility, and loss or heter-
ogeneity of 3D-structures. The first general conclusion we can draw from the data here presented is that none of 
such biophysical properties, taken alone, allows clustering of the H versus the M LCs; on the contrary, amyloido-
genicity seems to stem from the co-existence of more than one of the biophysical factors explored.
According to our assessments of fold stability through CD and ANS fluorescence, the examined H LCs dis-
play Tmapp values lower than the M LCs; on average the Tmapp for H LCs is 53.6 °C vs. an average Tmapp value of 
62.8 °C for the M LCs. Such a trend is mirrored by the average onset temperature for the ANS signal, which is 
55.0 °C for H LCs vs. 63.0 °C for the M LCs. Such an overall observation would be in keeping with the idea that 
amyloidogenicity correlates with lower fold stability, as previously suggested32; however, M7 and M10 are nota-
ble exceptions showing Tmapp values comparable with some of the H LCs. However, M7 was found present at 
high concentration in vivo, and yet no aggregation or toxicity was observed at presentation and during the later 
follow-up times (Table 1 and Table S1). This marked variability stresses the importance of using large set of pro-
teins and it likely explains the contained differences in Tmapp recently observed by others between amyloidogenic 
and M LCs23: Andrich et al. reports an interesting biophysical characterisation of nine full length LCs but only 
four are of the λ isotypes and thus could be compared23.
Intriguingly, the low ANS fluorescence observed under native conditions suggests that bulk surface hydropho-
bicity does not play a main role in determining the H LC toxicity in their native state. Indeed, LC overall hydro-
phobicity (computed from the amino acid sequences - Table 2) indicates a comparable amount of hydrophobic 
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residues in all thirteen LCs. The Far-UV CD spectra that on average display a slightly more intense signal for M 
LCs (Figure S1) suggest that typically the latter contain very regular β structure, while H LCs spectra vary more 
markedly; however, the inference value of these observations is essentially of qualitative nature.
Contrary to the limited information offered by the spectroscopic analyses, controlled proteolysis provided a 
robust indication that M LCs are more rigid, or less dynamic, than H LCs. These are however divided into two 
subsets: H3, H6 H7, H9 and H16 are very efficiently proteolysed, while H10, H15 and H18 show slower cleavage 
kinetics. Inspection of the SDS-PAGE gels shows that the proteolysis pattern is different in different H LCs, sug-
gesting that the sequence of proteolytic events, and not only their kinetics, may be characteristic of each H LC. It 
is also remarkable that fold stability and kinetics of proteolysis do not necessarily correlate: M7 displays the lowest 
Figure 4. (A) Cartoon model of the crystal structure of the H9 homodimer, as representative of the tertiary 
and quaternary organization of all the LC structures determined in this work. The two LC monomers are 
coloured in grey and blue. The VL interface region on the blue monomer is coloured in orange. The spheres 
indicate the position of N/C termini. (B) Superposition of the dimeric VL (top panel) and CL (bottom panel) 
domains. One VL/CL domain (coloured in grey) was fixed for all the seven structures and the second is coloured 
according to the different LCs (H3 yellow; H6 green; H7 dark blue; H9 blue; H10 magenta; M7 red; M8 lime 
green). VL domain from M8 is shown only in panel E. (C) Superposition of a single VL domain (grey) from each 
of the seven LC structures. The complementarity-determining regions (CDRs) belonging to different LCs are 
coloured following the B panel colour code. (D) Cartoon model of a single VL domain from the structure of H9 
showing in orange the regions involved in the VL – VL interaction. The residues represented as sticks indicate 
the positions involved in the VL – VL interface that are conserved among of all LCs structures. (E) Cartoon 
representation of H9 (grey-blue) and of M8 (grey-lime green) where the grey VL are superposed and oriented 
as in B (top panel). The different orientation of the second VL domain is apparent in the H9 dimer, chosen as an 
example, compared to the M8 dimer. Labels indicate the β-strand identification number.
www.nature.com/scientificreports/
8ScieNtific RePORtS | 7: 16809  | DOI:10.1038/s41598-017-16953-7
Tmapp among the M LCs, but also very slow proteolysis kinetics; H3, H6 and H9 show relatively high Tmapp, within 
the H group, but are almost instantly proteolysed by trypsin. Recently, Morgan et al. reported faster kinetics of 
proteolysis for three amyloidogenic LCs due to kinetic instability of the native state22. In the present study we 
cannot distinguish whether the different kinetics of proteolysis are due to thermodynamic or kinetic instability, 
which are anyway linked to increased protein dynamics.
Among the experiments here reported, limited proteolysis provided the best correlation between LC behav-
iour and amyloidogenicity, showing a pronounced proteolytic trend in the H LC group; such consideration may 
be relevant under different aspects. Increased protein dynamics is considered a risk factor for aggregation propen-
sity33. Furthermore, previous studies suggest that the LC fragments released by proteolytic cleavage of full length 
LCs are more amyloidogenic than the LCs themselves, and may be important species favouring the process of LC 
aggregation21,22,34. Indeed, the existence of LC fragments in amyloid deposits in vivo has been uncontrovertibly 
demonstrated4,34. Although the site (i.e. whether it occurs in the circulation, in the extracellular space or inside 
cells) and timing (before or after amyloid formation) of LC proteolysis is still a matter of debate, the strong cor-
relation between amyloidogenicity and the ability to be easily proteolysed is stimulating, and suggests that H LCs 
may release pathogenic peptides much more efficiently than M LCs.
Although crystals could not be grown for the whole set of LCs, the relevant number of crystal structures 
solved, allows us to extend the discussion to the relationships between the LC biophysical and structural prop-
erties. Firstly, and somewhat unexpectedly, the most temperature- and trypsin-sensitive LCs (H3, H6, H7, H9) 
could be successfully crystallized. Such results indicate that, although characterized by low stability and high 
dynamics within the group tested, these LCs display a properly folded native structure devoid of large disordered 
regions that would hamper crystal growth. Secondly, the high level of conservation of the tertiary and quaternary 
assemblies in the seven LC structures here reported strongly suggests that the differences observed in the biophys-
ical traits mainly depend on sequence variability, and not on major structural rearrangements. Such a considera-
tion would imply that the intrinsic sequence variability, mainly located in the VL domains, does not translate into 
extended conformational changes but is responsible for the LC behaviour at the molecular level (reflected by the 
biophysical traits and amyloidogenicity).
Intriguingly, plotting percentage of uncleaved LC at the end of the proteolysis experiments against Tmapp 
(determined by Far-UV) shows that H and M LCs could be clearly clustered (Figure S3). These observations 
suggest basic criteria for the design of ligands that may decrease LC amyloidogenicity. Molecules acting on the 
LC dimers, stabilizing the quaternary structure upon binding, as is the case of Tafamidis for the transthyretin 
tetramer (i.e. stabilization of the quaternary structure upon binding)35, would result in an increased LC fold sta-
bility, and in a reduction of overall protein flexibility, the two biophysical traits that were shown here to correlate 
more strongly with LC amyloid propensity. Specifically, within LC dimers, targeting the dimer region encompass-
ing the VL domains appears as the proper strategy to combat LC amyloidogenicity at its biophysical roots: indeed, 
small-molecule ligands stabilizing VL dimers have recently been shown to inhibit amyloid formation36.
In conclusion, analysis and comparison of the different biophysical properties of H vs. M LCs suggests that no 
single molecular determinant by itself can account for the observed toxicity and aggregation trends, thus stress-
ing the value of biochemical and biophysical studies based on a large pool of proteins rather than on pairwise 
comparisons. However, fold stability and protein dynamics (as assessed by proteolysis), but not surface hydro-
phobicity in the native state, or overall 3D-structure rearrangements of the native state, appear to play main roles 
in determining LC amyloidogenic behaviour. Our study therefore suggests that in vivo amyloidogenicity would 
be the result of concurrent biophysical traits that, as in our pool of proteins, may not necessarily all be present in 
each toxic LC at the same level.
Materials and Methods
Patients’ samples. Urine and bone marrow plasma cells were obtained from patients during routine diag-
nostic procedures at the Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo 
(Pavia, Italy). Acquisition, storage and use of biological samples for research purposes were approved by the 
Institutional Review Board of Fondazione IRCCS Policlinico San Matteo Pavia; all methods were performed in 
accordance with the relevant guidelines and regulations. Written informed consent was received from partici-
pants prior to inclusion in the study. The presence of tissue amyloid deposits and amyloid organ involvement were 
defined according to the International Consensus Panel Criteria37,38. LC cardiotoxicity was evaluated on the basis 
of clinical, echocardiography and biochemical parameters39 (Table S1).
In parallel to amyloidogenic cardiotoxic LC (H), non-amyloidogenic LC from multiple myeloma patients (M) 
were used. All the monoclonal LCs included in the study, belong to the λ isotype.
Cloning of complete monoclonal free LC nucleotide sequences. Total RNA was extracted from 
107 bone marrow mononuclear cells using TRIzol reagent (Life Technologies, Paisley, United Kingdom). 
Monoclonal variable (VL) region nucleotide sequences were cloned by an inverse-PCR strategy that preserves 
the original sequence at 5′ and 3′ ends40. The PCR fragment was ligated into the pCR®2.1Vector (TA Cloning 
Kit; Life Technologies) and cloned into the TOP10 E. coli cells. After recombinant plasmid purification, insert 
was sequenced. In order to obtain the original full-length monoclonal LC (variable and constant regions, approx-
imately 650 bp, from codons +1 to +215), standard RT-PCR was employed using the same marrow RNA, a 
forward patient-specific primer (dictated by codons +1 to +7 of the monoclonal V sequence) and a universal 
reverse Cλ carboxyterminal cloning primer, corresponding to the last amino acids of the constant region (codons 
+208 to +215, 5′-TGAACATTCTGTAGGGGCCACTGT-3′). To determine the presumed germline genes of VL 
regions, sequence alignment was made with the current releases of EMBL-GenBank, V-BASE (V BASE Sequence 
Directory, MRC Centre for Protein Engineering, Cambridge, UK) and IMGT sequence directories. The gene 
sequences of the LCs here discussed have been deposited in the GenBank database: KC433670 (H3), KY471433 
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(H6), KC433671 (H7), KY471435 (H9), KY471432 (H10), KY471436 (H15), KY471437 (H16), KY471434 (H18), 
KY471441 (M2), KY471438 (M7), KY471439 (M9), KY471440 (M10).
LC purification from urines. LC were purified to homogeneity from 24 h urine collection. Urines, imme-
diately combined with 0.1% sodium azide (w/v), were centrifuged at 3000 x g for 30 min. Ammonium sulfate was 
added to the supernatant (65% saturation) and, after overnight incubation, samples were centrifuged at 3000 x g 
for 30 min. The precipitates were solubilized in 20 mmol/L sodium phosphate, pH 7.0, and dialyzed against the 
same buffer. All steps were performed at 4 °C. LC were purified by anion exchange chromatography on an AKTÄ 
Purifier® FPLC system (GE-Healthcare, Piscataway, NJ, USA), using a HiPrep16/10 Q FF column, equilibrated 
in 20 mM sodium phosphate, pH 7.0. Bound proteins were eluted with a 0 up to 1 M sodium chloride linear gra-
dient. H6, M2, M9 were purified using a cation exchanger column (HiPrep16/10 SP FF), equilibrated in 20 mM 
Tris-HCl, pH 8.0, and was eluted with a 0 up to 1 M sodium chloride linear gradient. The homogeneity of the 
isolated species was assessed by 12% SDS-PAGE. The final protein concentration was determined using the Pierce 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) and bovine serum albumin as standard.
Production of recombinant patient-derived LC. Recombinant LCs of selected patients were produced 
according to30. Briefly, heterologous proteins, produced in the cytoplasm as inclusion bodies, were retrieved and 
subjected to a renaturation procedure, followed by purification by means of ion exchange and size exclusion chro-
matography. Recombinant LCs were biochemically characterized by linear MALDI-TOF mass spectrometry and 
circular dichroism analyses, in order to verify sequence, homogeneity and correct folding. Gel filtration analysis 
indicates that all LCs used in this work were dimeric in solution (data not shown).
Circular dichroism spectroscopy. Circular dichroism experiments, in the Far- and Near –UV regions, 
were carried out on a J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a Peltier system 
for temperature control. All experiments were carried out in 50 mM sodium phosphate pH 7.4. For the Far-UV 
region, protein concentration was 0.2 mg/mL in a cuvette with a pathlength of 0.1 cm. Spectra were recorded from 
260 to 190 nm, whereas temperature ramps from 20 to 80 °C (monitored wavelength 202 nm, temperature slope 
60 °C/hour). Spectra and temperature ramps were performed in triplicate for each LC except for M8 for which no 
BJ purified material is available. For the Near-UV region, protein concentration was 1 mg/mL in cuvettes with a 
pathlength 1 cm. Spectra were recorded from 350 to 250 nm, whereas temperature ramps from 20 to 80 °C (mon-
itored wavelength 288 nm, temperature slope 60 °C/hour). Tmapp was calculated as the first-derivative minimum 
of the temperature ramps. Spectra recorded on cooled samples after temperature ramps confirmed that LC dimers 
unfold irreversibly as previously reported22.
ANS fluorescence. 8-Anilino-1-naphthalenesulfonic acid (ANS) binding experiments were carried out at 
20 °C and at 0.1 mg/mL protein concentration in 50 mM sodium phosphate pH 7.4. Each experiment was per-
formed adding ANS to a final concentration of 100 µM. After every addition, ANS fluorescence emission spectra 
were recorded in the 420–550 nm range with excitation at 390 nm, excitation and emission slits were set at 5 nm, 
with a scanning speed of 50 nm/min. When ANS concentration was 100 µM, its signal was monitored at  490 nm 
along a temperature ramp starting from 20 to 80 °C (temperature slope 60 °C/hour) in a 1 cm path length cuvette.
Limited proteolysis. LCs at a concentration of 0.8 mg/mL, were incubated at 37 °C in 50 mM sodium phos-
phate, 1 M urea at pH 7.4, using a bovine trypsin/LC molar ratio of 1:100. The first sample was collected imme-
diately after trypsin addition and then after 10′, 20′, 30′, 60′, 90′, 120′, 150′, 180′. Subsequently, they were diluted 
in denaturating and reducing sample buffer (NuPAGE, Invitrogen), heated at 95 °C for 3 min and analysed by 
SDS-PAGE. Protein bands corresponding to uncleaved LC monomers were quantified by densitometric analysis 
using ChemidocTM MP System (Bio-Rad). In order to rule out that the very fast proteolysis of H3, H6, H7, H10 
was due to partial or total unfolding several controls were performed in presence of 1 M urea: first the Far-UV 
spectra are superposable to the ones without urea; secondly the temperature unfolding curves monitored by 
Far-UV indicate that the unfolding process is starting at a temperature beyond 37 °C. For three LCs (H3, H6 and 
H9), which displayed very fast kinetics of proteolysis, parallel experiments were performed also in the presence 
of 0.5 M and 0 M urea, confirming under both conditions a trend for very fast proteolysis for these H LCs (see 
Figure S1). The latter observations further confirm that the fast kinetics of proteolysis were not artifacts related 
to excessive urea concentration.
Crystallization and X-ray structure determination. LCs were crystallized using sitting drops or hang-
ing drops techniques. Each protein was solubilized in 50 mM sodium phosphate pH 7.4 at a concentration of 
8.5–10 mg/mL at 20 °C. Crystals were obtained in: H3: 0.1 M Sodium cacodylate pH 6.5, 27% w/v PEG 2000 MME 
(Stura screen, Molecular dimensions); H6: 0.1 M Bicine pH 9.0, 2% w/v 1,4-Dioxane, 10% w/v PEG 20 K (Crystal 
Screen I/II, Hampton); H7: 0.1 M HEPES pH7.5, 10% 2-propanol, 20% w/v PEG 4 K (JBS screen, Jena Bioscience); 
H9: 0.1 M Sodium citrate pH 5.5, 16% w/v PEG 4000, 10% v/v 2-propanol (Stura screen, Molecular dimensions); 
H10: 0.05 M KBr, 30% PEG 2000 (JCSG screen, Molecular dimensions); M7: 0.1 M MMT (Malic acid, MES and 
Tris-base buffer) pH 4.0, 25% w/v PEG 1.5 K (microseeding with M8 crystals) (PACT screen, Molecular dimen-
sions); M8: 0.2 M sodium acetate pH 4.6, 2.0 M NaCl (Crystal Screen I/II, Hampton).
Crystals were cryoprotected adding 33% glycerol to mother liquor and then flash frozen in liquid nitrogen. 
X-ray diffraction data were collected at ESRF (European Synchrotron Radiation Facility of Grenoble–France) at 
the beam lines: ID29, ID30, ID23-2, BM14. The diffraction data were analysed and processed using MOSFLM 
and XDS41,42, the crystal symmetry was then verified by POINTLESS43 and the intensities were merged and scaled 
with SCALA44. The crystal structures were determined by molecular replacement using PHASER, BALBES and 
MOLREP45–47. In order to perform the molecular replacement for H7, the full length LC (pdb: 1JVK)10 was used 
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as search model. Then for the subsequent molecular replacements, LC structures determined in house were 
used. H9 initial model was generated by ARP-wARP48. The initial models were subjected firstly to a rigid-body 
refinement and then to a restrained and TLS refinement using Phenix Refine, Refmac5 and Buster49–51. Manual 
model building, water picking and structure analysis were then performed using Coot52. Dimer interface analysis 
shown in Table S3 was performed using PISA53. Fab elbow angles were calculated with phenix.fab_elbow_angle49. 
Figures of crystallographic structures were done using PyMOL and CCP4mg54.
The atomic coordinates and the structure factors of the seven structures of LCs have been deposited in the 
Protein Data Bank with the following accession numbers: 5MTL (H3), 5MUD (H6), 5MUH (H7), 5M6A (H9), 
5M76 (H10), 5MVG (M7), 5M6I (M8).
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